Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (115)
ARTG (99)
Prescription medicine registration (52)
Australian Public Assessment Report (AusPAR) (31)
Designation or determination (31)
Prescription medicine evaluation (9)
Prescription medicine decision summary (2)

Date

2024 (25)
2023 (33)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (12)
2013 (16)
2012 (6)
2011 (4)
2009 (10)
2008 (6)
2007 (6)
2006 (10)
2005 (1)
2003 (1)
2002 (7)
2000 (1)
1998 (1)
1997 (5)
1996 (1)
1993 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

339 result(s) found, displaying 11 to 20

SEGLUROMET 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEGLUROMET 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEGLUROMET 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEGLUROMET 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STEGLATRO 15 ertugliflozin 15 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STEGLATRO 5 ertugliflozin 5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
INTEGRILIN eptifibatide (as acetate) 75mg/100mL injection vial Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
INTEGRILIN eptifibatide (as acetate) 20mg/10mL injection vial Cancelled under Section 30(1)(c) of the Act

23 April 2024

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
WELIREG Merck Sharp & Dohme (Australia) Pty Ltd

Apr-2024

Prescription medicine evaluation

Active ingredient: belzutifan.
KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd

Apr-2024

Prescription medicine evaluation

Active ingredient: pembrolizumab.

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.